Hepatology Communications

Article	Citations
A genetic variant in the CD40 gene is related to HBV infection in the Chinese Han population	148
Issue Information	134
Targeting hepatocyte-specific SLC2A8 blocks hepatic steatosis and dissociates TCA cycle flux inhibition from glutamine anaplerosis	132
HBV DNA polymerase regulates tumor cell glycogen to enhance the malignancy of HCC cells	96
CD8 TRM-like T cells expressing perforin and IFN-γ define a pediatric activated T-cell acute liver failure endotype	77
Quality improvement in hepatology requires a chronic care framework	69
Reduced short-term survival following liver transplant in patients with acute-on-chronic liver failure: Reevaluating OPTN data	69
Erratum: Pervasive role of pruritus in impaired quality of life in patients with primary biliary cholangitis: Data from the GLIMMER study	66
Clinical decision support automates care gap detection among primary care patients with nonalcoholic fatty liver disease	65
Association between widespread pain and associated symptoms in patients with cirrhosis	65
Clinical and genetic definition of serum bilirubin levels for the diagnosis of Gilbert syndrome and hypobilirubinemia	64
Baseline serum HBV RNA is associated with the risk of hepatitis flare after stopping nucleoside analog therapy in HBeAg-negative participants	62
A prospective investigation of serum bile acids with risk of liver cancer, fatal liver disease, and biliary tract cancer	53
Effect of glucagon-like peptide-1 receptor agonists on histologic MASH: A meta-analysis of randomized controlled trials	52
Community-level social vulnerability and individual socioeconomic status on liver transplant referral outcome	52
Immunologic landscape of human hepatic hemangiomas and epithelioid hemangioendotheliomas	51
Medical malpractice claims in Hepatology: Rates, Reasons, and Results	50
Infections in decompensated cirrhosis: Pathophysiology, management, and research agenda	49
Visualizing in situ viral replication across the natural history of chronic HBV infection	48
Pain in chronic liver disease compared to other chronic conditions: Results from a contemporary nationally representative cohort study	46
The truth of the matter: will immune-tolerant chronic hepatitis B patients benefit from antiviral treatment?	45
Aramchol attenuates fibrosis in mouse models of biliary fibrosis and blocks the TGFβ-induced fibroinflammatory mediators in cholangiocytes	44
Deletion of sphingosine 1-phosphate receptor 1 in myeloid cells reduces hepatic inflammatory macrophages and attenuates MASH	43
Increasing nonalcoholic fatty liver disease–related mortality rates in the United States from 1999 to 2022	43
Mesenchymal stem/stromal cells armored by FGF21 ameliorate alcohol-induced liver injury through modulating polarization of macrophages	43

Ranking of transarterial and targeted therapies for advanced hepatocellular carcinoma in the era of immuno‐oncology: A network meta‐analysis of randomized sorafenib‐controlled trials	42
Co‐regulation of hepatic steatosis by ferritinophagy and unsaturated fatty acid supply	42
Granulomatous liver diseases	41
Resolution of hepatic fibrosis after ZFN-mediated gene editing in the PiZ mouse model of human α1-antitrypsin deficiency	40
Management of alcohol withdrawal syndrome in patients with alcohol-associated liver disease	38
Disproportionate increases in alcohol-associated hepatitis incidence in women and individuals of low socioeconomic status: A population-based study using the Rochester epidemiology project database	38
Development and evaluation of a virtual reality driving test for patients with cirrhosis	38
Naltrexone for alcohol use disorder: Hepatic safety in patients with and without liver disease	38
Complementary and alternative medicines and liver disease	38
Zinc fingers and homeoboxes 2 is required for diethylnitrosamine‐induced liver tumor formation in C57BL/6 mice	37
Copper deficiency is an independent risk factor for mortality in patients with advanced liver disease	37
Noninvasive pathway for stratifying fibrosis in suspected metabolic dysfunction and alcohol-associated liver disease (MetALD)	37
Atorvastatin for patients with cirrhosis. A randomized, placebo-controlled trial	37
High prevalence of liver fibrosis among general population: a Romanian population-based study: Erratum	36
Letter to the Editor: Rifamycin SV MMX was superior to placebo, but was the comparison appropriate?	36
Depression and anxiety management in cirrhosis	36
CD36 in liver diseases	35
Hepatocyte-derived liver progenitor-like cells attenuate liver cirrhosis via induction of apoptosis in hepatic stellate cells	35
Hepatocellular carcinoma cells downregulate NADH:Ubiquinone Oxidoreductase Subunit B3 to maintain reactive oxygen species homeostasis	35
SARS-CoV-2 viral liver aggregates and scarce parenchymal infection implicate systemic disease as a driver of abnormal liver function	35
GATA4 downregulation enhances CCL20-mediated immunosuppression in hepatocellular carcinoma	35
Progression to cirrhosis is similar among all ages in nonalcoholic fatty liver disease, but liver-related events increase with age	34
Human VH-based chimeric antigen receptor T cells targeting glypican 3 eliminate tumors in preclinical models of HCC	34
Risk-stratified surveillance for hepatocellular carcinoma	34
Increased MASH-associated liver cancer in younger demographics	34
Behavioral weight-loss interventions for patients with NAFLD: A systematic scoping review	34
Lumican–TLR4 interaction accelerates hepatic fibrosis by activating hepatic stellate cells	33
EBV enhances immunotherapy sensitivity in intrahepatic cholangiocarcinoma through cGAS-STING pathway activation	33
Loss of heat shock factor 1 promotes hepatic stellate cell activation and drives liver fibrosis	32
Gut microbiota and metabolic biomarkers in metabolic dysfunction–associated steatotic liver disease	32
A need for confirmatory testing of isolated HBcAb-positive results in screening programs	32
Design, implementation, and impact of a cirrhosis-specific remote patient monitoring program	32
Precipitous changes in nomenclature and definitions—NAFLD becomes SLD: Implications for and expectations of AASLD journals	32
Evolutional transition of HBV genome during the persistent infection determined by single-molecule real-time sequencing	32
A qualitative patient interview study to understand the experience of patients with nonalcoholic steatohepatitis	31
Serologic extracellular matrix remodeling markers are related to fibrosis stage and prognosis in a phase 2b trial of simtuzumab in patients with primary sclerosing cholangitis	31
Midodrine versus placebo in patients with acute-on-chronic liver failure with ascites—A randomized trial (MIDAS trial)	30
HBV core protein enhances WDR46 stabilization to upregulate NUSAP1 and promote HCC progression	30
Sirtuin3 promotes the degradation of hepatic Z alpha-1 antitrypsin through lipophagy	30
CD63-high macrophage-derived exosomal miR-6876-5p promotes hepatocellular carcinoma stemness via PTEN/Akt-mediated EMT pathway	30
Fatty acid synthesis is indispensable for Kupffer cells to eliminate bacteria in ALD progression	30
Lipid droplet deposition in the regenerating liver: A promoter, inhibitor, or bystander?	29
A nationwide study of primary biliary cholangitis prevalence, geographic distribution, and health care providers	29
	28
Cellular communication networks in fibrosis: Insights from the MASLD pig model	28
Alpha-fetoprotein: Past, present, and future	28
Repurposing of the analgesic Neurotropin for MASLD/MASH treatment	27
Fecal microbiota transplantation in chronic liver disease: Current and future state of the art	27
Erratum: Clinical spectrum and genetic causes of mitochondrial hepatopathy phenotype in children	27
Differentiation of biliary atresia using a rapid point-of-care matrix metalloproteinase-7 assay: A multicenter diagnostic study	27

Falls and malnutrition are associated with in-hospital mortality in patients with cirrhosis	26
The impact of multidrug-resistant microorganisms on critically ill patients with cirrhosis in the intensive care unit: a cohort study	26
Long-term weight changes are associated with initial weight changes after nonalcoholic fatty liver disease diagnosis	26
Home exercise, branched-chain amino acids, and probiotics improve frailty in cirrhosis: A randomized clinical trial	25
A plasma peptidomic signature reveals extracellular matrix remodeling and predicts prognosis in alcohol-associated hepatitis	25
Meaningful differences in patient-reported outcome measurement scores in liver disease	25
Dexamethasone mitigates remdesivir-induced liver toxicity in human primary hepatocytes and COVID-19 patients	25
Long-term management and treatment of acute intermittent porphyria with recurring attacks using pharmacological prophylaxis	25
Defining the Society of Pediatric Liver Transplantation (SPLIT) research agenda: A Delphi consensus project	24
Steroid responsiveness in alcohol-associated hepatitis is linked to glucocorticoid metabolism, mitochondrial repair, and heat shock proteins	24
A randomized trial of mailed outreach with behavioral economic interventions to improve liver cancer surveillance	24
Increasing national trend of direct-acting antiviral discontinuation among people treated for HCV 2016–2021	24
Screening and management of portal hypertension and varices in cirrhosis: Expert perspectives	23
Toll-like receptor 2 activation in monocytes contributes to systemic inflammation and alcohol-associated liver disease in humans	23
The global prevalence and impact of steatotic liver disease and viral infections: A systematic review and meta-analysis	23
Evaluation of the definition of hyperdynamic circulation in patients with cirrhosis and ascites	23
CD4+ T-cell subsets in autoimmune hepatitis: A review	23
Diet composition impacts the natural history of steatotic liver disease	23
Thyroid hormone acts independently of the thyroid hormone receptor beta in hepatocytes to improve systemic insulin sensitivity	23
Patient-reported symptoms and interest in symptom monitoring in HCC treated with locoregional therapies: A qualitative study	23
Association of preoperative IL-6 levels with overt HE in patients with cirrhosis after TIPS	22
iPSC-based hepatic organoids reveal a heterozygous MYO5B variant as driver of intrahepatic cholestasis	22
A strategy for varices screening based on acoustic radiation force impulse combined with platelet (CHESS2001): An alternative of Baveno VI criteria: Erratum	22
Reply: Hepatopulmonary syndrome associated with common variable immunodeficiency: Is it reasonable to investigate?	22
Clinical predictors and noninvasive imaging in Fontan-associated liver disease: A systematic review and meta-analysis	22
Erratum: Binge drinking at time of bariatric surgery is associated with liver disease, suicides, and increases long-term mortality	22
Efficacy and safety of fenofibrate addition therapy in patients with cirrhotic primary biliary cholangitis with incomplete response to ursodeoxycholic acid	22
Clinical outcomes in MetALD compared with ALD in patients referred for liver transplant evaluation	22
Erratum: Use and outcome of transjugular intrahepatic portosystemic shunt in hospitalized patients Germany:Nationwide study (2007-2018)	22
Reply: Antibiotic prophylaxis in palliative patients with cirrhosis: Stewardship or gatekeeping?	22
Leukemia inhibitory factor promotes human cholangiopathies, and its inhibition improves cholestasis in Abcb4 −/− mice	21
Pragmatic strategies to address health disparities along the continuum of care in chronic liver disease	21
Impact of social determinants of health on hepatocellular carcinoma surveillance, treatment, and health care costs	21
Tetrahydroxylated bile acids improve cholestatic liver and bile duct injury in the Mdr2−/− mouse model of sclerosing cholangitis via immunomodulatory effects	21
Aspirin is associated with a reduced incidence of liver disease in men	21
Functional involvement of endothelial lipase in hepatitis B virus infection	21
Extracellular matrix protein 1 binds to connective tissue growth factor against liver fibrosis and ductular reaction	21
A healthy lifestyle is prospectively associated with lower onset of metabolic dysfunction–associated steatotic liver disease	21
Low awareness of MASLD among U.S. adults: Trends from NHANES 2017–2023	21
Amphisome plays a role in HBV production and release through the endosomal and autophagic pathways	21
Gut microbial metabolites in MASLD: Implications of mitochondrial dysfunction in the pathogenesis and treatment	21
Acute on chronic liver failure: prognostic models and artificial intelligence applications	21
Reproducibility of vibration-controlled transient elastography, controlled attenuation parameter, and blood tests in cirrhosis	20
Inhibition of CBP/β‐catenin signaling ameliorated fibrosis in cholestatic liver disease	20
HCC surveillance in hepatitis C: A longitudinal algorithm improves alpha-fetoprotein screening	20
Risk of HCC decreases in HBV-related patients with cirrhosis acquired recompensation: A retrospective study based on Baveno VII criteria	20
	20
Growth hormone deficiency and NAFLD: An overlooked and underrecognized link	20
An overview of the cholesterol metabolism and its proinflammatory role in the development of MASLD	20
Sodium cholate ameliorates nonalcoholic steatohepatitis by activation of FXR signaling	19
Erratum: BTLA deficiency promotes HSC activation and protects against hepatic ischemia-reperfusion injury	19
	19
NME2 modulates HCC progression through 4EBP1 phosphorylation and autophagy regulation independent of mTOR	19
Erratum: Gut microbiota and metabolic biomarkers in metabolic dysfunction-associated steatotic liver disease (MASLD)	19
Blood bacterial DNA signatures in a prospective cohort of patients with MASLD cirrhosis	19
Novel metabolic phenotypes for extrahepatic complication of nonalcoholic fatty liver disease: Erratum	19
The burden of extrahepatic organ failures in European patients with cirrhosis	18
Mouse model of NASH that replicates key features of the human disease and progresses to fibrosis stage 3	18
Heterogeneity of treatment response to beta-blockers in the treatment of portal hypertension: A systematic review	18
Hepatitis C is associated with more adverse pregnancy outcomes than hepatitis B: A 7‐year national inpatient sample study	18
miR-34a regulates macrophage-associated inflammation and angiogenesis in alcohol-induced liver injury	18
Gut microbiota-produced vitamin B6 mitigates alcohol-associated liver disease by attenuating hepatic oxidative stress damage	18
Tenofovir alafenamide for prevention of HBV reactivation in HBsAg-negative, anti–HBc-positive patients undergoing rituximab-based chemotherapy: A multicenter randomized controlled trial	18
Epigenetic deregulation of MLF1 drives intrahepatic cholangiocarcinoma progression through EGFR/AKT and Wnt/β-catenin signaling	18
Adipose tissue insulin resistance exacerbates liver inflammation and fibrosis in a diet-induced NASH model	18
METTL3 inhibits liver fibrosis via RBX1 stability and TXNIP-mediated ferroptosis	17
Genetic variants associated with immune-mediated liver injury from checkpoint inhibitors	17
Long-term HBV infection of engineered cultures of induced pluripotent stem cell-derived hepatocytes	17
Interleukin-18 binding protein protects against metabolic steatohepatitis	17
Outcomes of patients with acute liver failure not listed for liver transplantation: A cohort analysis	17
A novel experimental model of MetALD in male mice recapitulates key features of severe alcohol-associated hepatitis	17
Hepcidin inhibits hepatocyte apoptosis through the PERK pathway in acute liver injury and fibrosis	17
Collagen in hepatocellular carcinoma: A novel biomarker and therapeutic target	17
EGFR activation in cholangiocytes promotes extrahepatic bile duct regeneration after injury	17
Population screening for cirrhosis	17
Zinc supplementation to improve prognosis in patients with compensated advanced chronic liver disease: a multicenter, randomized, double-blind, placebo-controlled clinical trial	17
Reply: Detrimental effects of diabetes mellitus in alcoholic liver disease	17
Hepatocyte dedifferentiation in 2D culture reveals extensive transcriptomic and proteomic rewiring	17
The dual roles of natural killer cells in liver immunity and tolerance: Implications for health and disease	17
Clinical utility of two-step hepatitis E virus IgM antibody testing in a low-prevalence setting: A 10-year retrospective multicenter study	17

Elevated FBXL18 promotes RPS15A ubiquitination and SMAD3 activation to drive HCC	17
Prevalence of at-risk NASH and its association with metabolic syndrome in US adults with NAFLD, 2017–2018	16
Common variable immunodeficiency disorder-related liver disease is common and results in portal hypertension and an increased risk of death	16
Bile acid conjugation deficiency causes hypercholanemia, hyperphagia, islet dysfunction, and gut dysbiosis in mice	16
Monitoring quality of care in hepatocellular carcinoma: A modified Delphi consensus	16
Incidence, clinical characteristics, and risk factors associated with recurrent alcohol-associated hepatitis	16
Secretion of the HBV small surface antigen is driven by an ER autophagic pathway	16
Activin B promotes the initiation and progression of liver fibrosis	16
Lysophosphatidic acid receptor 1 antagonist (EPGN2154) causes regression of NASH in preclinical NASH models	16
Validating new coding algorithms to improve identification of alcohol-associated and nonalcohol-associated cirrhosis hospitalizations in administrative databases	16
Low vitamin A levels are associated with liver-related mortality: a nationally representative cohort study	16
Atorvastatin favorably modulates a clinical hepatocellular carcinoma risk gene signature	16
	16
ARID1A deficiency promotes malignant proliferation of hepatocellular carcinoma by activating HDAC7/ENO1 signaling pathway	16
The most impactful findings on liver cancer in 2023	16
Neighborhood disparities and metabolic dysfunction–associated steatotic liver disease in children with overweight or obesity	16
Dysregulated meta-organismal metabolism of aromatic amino acids in alcohol-associated liver disease	16
Post-translational modifications drive the effects of HMGB1 in alcohol-associated liver disease	16
Severe acute hepatitis of unknown etiology in a large cohort of children	16
Evidence-based criteria for identifying at-risk individuals requiring liver disease screening	16
Clinical and genetic risk factors for progressive fibrosis in metabolic dysfunction–associated steatotic liver disease	16
The impact of aging on liver health and the development of liver diseases	16
Deficiency of Ugcg in LSECs alleviates high-fat diet-induced MASLD	16
NUAK1 promotes metabolic dysfunction-associated steatohepatitis progression by activating Caspase 6–driven pyroptosis and inflammation	16
Profiling of cell‐free DNA methylation and histone signatures in pediatric NAFLD: A pilot study	15
Novel biomarkers for early detection of HCC in patients with MASLD or ALD	15
HBV-specific T-cell function is nonenhanced by tenofovir-induced decline in HBV viremia or HBsAg titer in chronic hepatitis B	15
Aerobic exercise interventions lead to MASH resolution in clinical trials: Pooled analysis using the MASH resolution index	15
Digital therapeutics lead to clinically significant body weight loss in patients with metabolic dysfunction–associated steatotic liver disease: A systematic review and meta-analysis	15
Statin use and risk of progression to liver cirrhosis in chronic hepatitis B independent of conventional risk factors: A nationwide study	15
MAPK15 controls intracellular lipid uptake and protects mammalian liver from steatotic disease	15
ROTEM-detected hypocoagulability is associated with major non-portal hypertensive bleeding in cirrhosis	15
A versatile method to profile hepatitis B virus DNA integration	15
Transversal psoas muscle thickness measurement is associated with response and survival in patients with HCC undergoing immunotherapy	15
Modulating intestinal neuroimmune VIPergic signaling attenuates the reduction in ILC3-derived IL-22 and hepatic steatosis in MASLD	15
The ferroptosis mediator ACSL4 fails to prevent disease progression in mouse models of MASLD	15
Spatial and functional polarization of cancer-associated fibroblasts with CXCR4-mediated immune modulation in hepatocellular carcinoma	15
Neurogastroenterology and motility disorders in patients with cirrhosis	15
Differential survival benefit of curative versus non-curative intent treatment in a real-world cohort with early and intermediate-stage hepatocellular carcinoma	15
An optimized peritonitis-induced ACLF model that reproduces the full spectrum of extrahepatic organ failures in mice	15
Disparities in presentation and management of chronic hepatitis B among Hispanics in a diverse safety net system	15
Assessing the risk of surgery in patients with cirrhosis	15
Predicting hepatic encephalopathy in patients with cirrhosis: A UK population–based study and validation of risk scores	15
Biliary microbial patterns in primary sclerosing cholangitis are linked to poorer transplant-free survival	14
Heterologous adenovirus‐vector/messenger RNA regimen is associated with improved severe acute respiratory syndrome coronavirus 2 humoral response in liver transplant recipients	14
Financial burden in a US cohort of patients with HCC	14
Role of mitogens in normal and pathological liver regeneration	14
Learn, adapt, act: A pragmatic approach for intervening on disparities in hepatocellular carcinoma outcomes	14
Microbially conjugated bile salts found in human bile activate the bile salt receptors TGR5 and FXR	14
Liver histology is associated with long-term clinical outcomes in patients with metabolic dysfunction–associated steatohepatitis	14
Erratum: Live-smart: A sequential, multiple assignment randomized trial to reduce falls in cirrhosis	14
Spermidine enhances the efficacy of adjuvant in HBV vaccination in mice	14
Liver iron levels are associated with HFE-hemochromatosis genotype, diet, adiposity, and disease in the UK Biobank	14
Portal cavernoma cholangiopathy: A systematic review of current understanding, clinical significance, and management	14
Serum levels of total bile acids are associated with an increased risk of HCC in patients with cirrhosis	14
Erratum: Community-level social vulnerability and individual socioeconomic status on liver transplant referral outcome	14
Seladelpar in patients with primary biliary cholangitis and compensated cirrhosis: Efficacy and safety from RESPONSE and ASSURE studies	14
Baveno VII for HCC: Are we there yet?	14
Hepatotoxicity of immune checkpoint inhibitors: What is Currently Known	14
Utility of pathologist panels for achieving consensus in NASH histologic scoring in clinical trials: Data from a phase 3 study	13
Cellular communication network factor 1‐stimulated liver macrophage efferocytosis drives hepatic stellate cell activation and liver fibrosis	13
Nicotinamide riboside enhances liver regeneration via the MCART1/ASB3 axis in obesity-compromised rats	13
GALAD outperforms aMAP and ALBI for predicting HCC in patients with compensated advanced chronic liver disease: A 12-year prospective study	13
HCV direct acting antiviral treatment leads to highly durable rates of ALT and AST lower than 30/19 criteria and improved APRI and FIB‐4 scores	13
Reply: Validation of MELD 3.0 in 2 centers from different continents	13
Ethanol disrupts hepatocellular lipophagy by altering Rab5-centric LD-lysosome trafficking	13
HMOX1+ macrophages determine immunosuppressive microenvironment and immunotherapy efficacy in hepatocellular carcinoma	13
Cytomegalovirus infection in patients with biliary atresia—further questions and possible solutions	13
Major Shifts in Outpatient Cirrhosis Care Delivery Attributable to the COVID‐19 Pandemic: A National Cohort Study	13
Sarcopenia is associated with osteopenia and impaired quality of life in children with genetic intrahepatic cholestatic liver disease	13
Issue Information	13
Deletion of adipocyte prohibitin 1 exacerbates high‐fat diet‐induced steatosis but not liver inflammation and fibrosis	13
Symptom burden and treatment patterns in primary biliary cholangitis: A systematic review and meta-analysis	13
Hepatocellular carcinoma in Fontan-associated liver disease: Incidence, risk stratification, and surveillance implications	13
Farnesoid X receptor alpha ligands inhibit HDV in vitro replication and virion infectivity	13
Clinical outcomes of intrahepatic cholestasis of pregnancy with versus without chronic hepatitis B: A retrospective analysis	13
Loss of phospholipase Cγ1 suppresses hepatocellular carcinogenesis through blockade of STAT3‐mediated cancer development	13
Problematic alcohol use and its impact on liver disease quality of life in a multicenter study of patients with cirrhosis	13
Reply: Sex for the purposes of MELD 3.0 calculation: When this differs from birth sex and implications for policy	13
Long-term outcomes after ICU admission in critically ill patients with liver cirrhosis: An Australian state-wide cohort study	13
The incidence and predictors of false-negative pancreatobiliary fluorescence in situ hybridization (PB-FISH) in biliary strictures: A prospective study	13
Erratum: Regulation of immune responses in primary biliary cholangitis: A transcriptomic analysis of peripheral immune cells	12
Reply: Critical commentary on the study comparing TIPS, tunneled peritoneal catheter, and ascites pump in refractory ascites	12
High prevalence of short telomeres in idiopathic porto-sinusoidal vascular disorder	12
Roles of RNA m6A modification in nonalcoholic fatty liver disease	12
HBV suppresses macrophage immune responses by impairing the TCA cycle through the induction of CS/PDHC hyperacetylation	12
Year in review: Liver cancer research in 2022: tumor microenvironment takes the central stage: Erratum	12
Second-line tacrolimus and mycophenolate mofetil in difficult-to-treat autoimmune hepatitis	12
Clinical and demographic predictors of survival for fibrolamellar carcinoma patients—A patient community, registry‐based study	12
Multidisciplinary clinic model enhances liver and metabolic health outcomes in adults with MASH	12
Genetics of liver disease in adults	12
Reply—Examining pregnancy outcomes in alcohol-associated hepatitis: A call for further research	12
Recent TIPS increases postoperative mortality: A national cohort study	12
A windfall year for HCC: The most impactful clinical papers in 2023	12
Maternal Western diet is associated with distinct preclinical pediatric NAFLD phenotypes in juvenile nonhuman primate offspring	12